Southwest Gas Holdings Beats Earnings Estimates, Plans Future Investments

Published 7 hours agoSWX

Southwest Gas Holdings Beats Earnings Estimates, Plans Future Investments

Southwest Gas Holdings, Inc. recently announced its fourth-quarter and full-year 2024 financial results, delivering strong earnings that surpassed analysts' expectations. The company's earnings per share (EPS) for Q4 2024 came in at $1.39, outperforming the consensus estimate of $1.15 by 20.9%. However, for the full year, EPS was $3.16, a decrease from the $3.64 recorded in 2023.

While earnings were up, the company faced mixed results in terms of revenue. Fourth-quarter operating revenues were $1.270 billion, slightly missing the consensus estimate of $1.373 billion. The full-year revenue of $5.11 billion marked a 5.9% decline from the previous year. According to Nasdaq, this performance was accompanied by a return on equity (ROE) of 8.1%, addition of 41,000 new meter sets, and stable operating and maintenance expenses per customer.

Looking ahead, Southwest Gas plans to invest $880 million in capital expenditures for 2025 to support growth, system improvements, and pipeline replacements. The company has forecast a compound annual growth rate of 6-8% for its rate base between 2025 and 2029. Furthermore, shareholders can anticipate a cash dividend of $0.62 per share for the second quarter of 2025, payable on June 2nd. This emphasis on strategic investments and shareholder returns aligns with Southwest Gas's commitment to improving infrastructure and expanding its customer base.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Chegg Cuts 22% of Workforce Due to AI Impact

Chegg Cuts 22% of Workforce Due to AI Impact

12 minutes agoCHGG

Chegg, the online education company, has announced it will lay off around 22% of its employees, which amounts to approximately 248 workers. This decision comes as part of a restructuring strategy prompted by the growing influence of AI technologies within the educational technology sector. Reuters highlighted the increasing challenge Chegg faces as students opt for free AI tools like ChatGPT for academic help, thus reducing Chegg's web traffic. The impact of AI doesn't stop there. Google's expansion of its AI Overviews has further kept internet users within its search ecosystem, lessening the need for students to use external educational resources such as Chegg. As a result, Chegg is planning to close its offices in the U.S. and Canada by the end of the year and will scale back on spending related to marketing, product development, and administration. This restructuring is expected to result in charges of $34 million to $38 million over the next two quarters. Despite these immediate costs, Chegg hopes to see significant savings in the near future, estimating reductions between $45 million and $55 million in 2025, increasing to $100 million to $110 million in 2026. However, the company reported a steep 31% drop in subscribers, bringing their total down to 3.2 million, alongside a 30% decrease in revenue, now at $121 million, during the first quarter of 2025. Such figures illustrate the fiscal pressures Chegg faces in adapting to the AI-driven educational landscape.

Altimmune Gears Up for Q1 2025 Earnings Amid Pemvidutide Developments

Altimmune Gears Up for Q1 2025 Earnings Amid Pemvidutide Developments

27 minutes agoALT

Altimmune, Inc. is drawing attention as it prepares to release its first-quarter 2025 earnings report. The company is expected to announce its financial results on May 8, 2025. This upcoming report has investors eager to see how the company is faring as it continues to advance its clinical trials. In the fourth quarter of 2024, Altimmune managed to exceed analysts' expectations by reporting a net loss of $23.2 million, or $0.33 per share, compared to the projected loss of $0.34 per share. This quarter saw significant investment in research and development, amounting to $19.8 million, with $13.6 million earmarked specifically for the development of pemvidutide. Reuters highlighted that this compound is of particular interest due to its ongoing trials targeting Metabolic Dysfunction-Associated Steatohepatitis (MASH). Recent developments in Altimmune's research efforts include the completion of enrollment in the Phase 2b IMPACT trial for pemvidutide, with results expected in the second quarter of 2025. Additionally, the FDA has approved Investigational New Drug (IND) applications for two more indications of pemvidutide, with corresponding Phase 2 trials expected to start by mid-2025. These advancements, coupled with optimistic revisions in earnings per share estimates by analysts at B. Riley, indicate growing investor confidence in Altimmune's direction as it unfolds.

Amazon's Market Valuation Remains Strong at $2.3 Trillion

Amazon's Market Valuation Remains Strong at $2.3 Trillion

57 minutes agoAMZN

As of May 12, 2025, Amazon.com Inc. (AMZN) maintains a robust market capitalization of approximately $2.3 trillion. This places the company among the elite in global business, alongside tech giants like Microsoft, Apple, Nvidia, and Alphabet, according to Forbes. Currently, Amazon's stock is trading at $208.3, reflecting a slight increase of $15.80 from the previous close. The stock experienced a trading range with an intraday high of $211.51 and a low of $202.22, on a volume of over 55 million shares. The activity underscores investor interest and confidence in its market performance. The strong market position of Amazon is largely attributed to its investments in artificial intelligence through Amazon Web Services (AWS), a major growth driver for the company. Furthermore, strategic partnerships, such as the collaboration with Rivian Automotive, have contributed positively to their stock performance, as reported by Nasdaq. These initiatives reflect Amazon's continued efforts to solidify its leadership in the market.

Goldman Sachs Assigns Neutral Outlook for Anheuser-Busch InBev

Goldman Sachs Assigns Neutral Outlook for Anheuser-Busch InBev

Goldman Sachs has maintained a "Neutral" rating for Anheuser-Busch InBev, setting a target price of €61. This appraisal comes on the heels of the company's market share gains and progress in optimizing its balance sheet. Anheuser-Busch InBev remains a dominant player in the global beer market, boasting significant shares in the United States, Mexico, and Brazil. Supporting these financial standings, Anheuser-Busch InBev has notably reduced its debt by roughly $40 billion since the acquisition of SABMiller in 2016, according to finance.yahoo.com. This reduction has strengthened its financial stability. The company also generates about $8 billion in free cash flow annually, which provides a robust foundation for ongoing operations and strategic initiatives. The company’s dividend is seen as secure, aligning with industry averages with a forward price-earnings multiple slightly above 18 times. Despite recent minor stock price fluctuations, including a closing price of 65.79 USD, Anheuser-Busch InBev's financial health and market dominance leave a positive impression in the industry.